EN DE
Watch Valneva SE for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Valneva SE (VLA) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Valneva SE stock €2.02, price €2.55, that is 20.8% below the price, quality 24 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0004056851

VS Valneva SE logo Thin data Nov 16, 2026

Valneva SE

VLA · PA

Expensive (fair value 21% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Revenue last quarter 28% below a year ago. 
Fair value €2.02 · Overvalued 
Quality 24/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −21.5 %/yr in EUR) 
Loss-making · -110.3% net margin (TTM) 
High debt 
Negative free cash flow 
Trails peers (2/10) 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Valneva SE for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€28.48 €1.76 Fair Value €2.02 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range €1.76 – €28.48 · fair‑value band €1.51 – €2.52 · the €2.55 price screens above the €2.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.

Follow Valneva in your weekly email

Every Wednesday you see whether Valneva is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

Show moreShow less

It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Stock analysis

Valneva SE (VLA) currently trades at €2.55, while our estimate is €2.02, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €1.51 (bear) to €2.52 (bull), the price of €2.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Valneva SE reported revenue of €175M in FY2025 versus €348M in FY2021, a compound −15.8%/yr. Reported net income was −€115M in FY2025.

Key figures

Market cap €484M Small · P/S ratio 3.37 · EPS (TTM) €−0.9000 · Net margin −110% · Return on equity −118% · Return on assets (EBIT) −12.3% (5-year average) · Operating margin −74.9% · Revenue (TTM) €143M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −21%, VLA screens richer than that median.

Fair Value

Bear €1.51 Fair Value €2.02 Bull €2.52
Price €2.55 · Downside -20.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 29
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 34
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 14
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Start year 2020 (pandemic). Over 10 years: +8.3% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−50.0% (2020) → −46.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

VLA screens overvalued: fair value 21% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Valneva SE with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −22.4% · Above median
Profitability
Return on assets −28.9% · Below median
Net margin (12 months) −110.3% · Bottom 25%
Operating margin (12 months) −74.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −27.7% · Bottom 25%
Balance sheet
Debt / equity 1.52× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.65× · Pricier than median
P/S (12 months) 3.45× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)3 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)24 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs VLA
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs VLA
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs VLA
argenx SE ARGX $950.95 $908.40 −4% vs VLA
CSL Limited CSL A$199.55 A$186.49 −7% vs VLA
Moderna, Inc MRNA $215.27 $135.64 −37% vs VLA
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs VLA
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs VLA
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs VLA
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs VLA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Valneva SE: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Valneva SE Fair Value". https://www.fairvalue-calculator.com/stock/VLA

Frequently asked questions

Is Valneva SE (VLA) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is €2.02 versus a price of €2.55, about 21% lower (overvalued).
What is the fair value of VLA?
Our estimate for Valneva SE is €2.02 (as of Nov 16, 2026), built from audited fundamentals. The current price: €2.55.
What is the quality score of VLA?
Valneva SE has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Valneva SE (VLA)?
Our calculated price target is the estimate of €2.02 (as of Nov 16, 2026). Cautious scenario €1.51, optimistic scenario €2.52. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Valneva SE stock forecast for 2026?
Our estimate puts fair value at €2.02, about 21% lower versus a price of €2.55 (overvalued). Cautious scenario €1.51, optimistic scenario €2.52. The calculation is refreshed regularly with new filings.
What is the revenue of Valneva SE (VLA)?
Valneva SE reported trailing-twelve-month revenue of about €143M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Valneva SE (VLA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Valneva SE it is €2.02 per share (as of Nov 16, 2026), against a price of €2.55.
Is Valneva SE stock overvalued or undervalued in 2026?
As of Nov 16, 2026, VLA trades above its calculated fair value: price €2.55, fair value €2.02, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VLA?
No. The price is what the market pays today (€2.55); the fair value is what the company's own numbers justify (€2.02). For Valneva SE the two are €0.5310 per share apart. That gap is exactly why we show both numbers side by side.
How much is Valneva SE worth?
The market values Valneva SE at about €484M (market capitalisation, as of Nov 16, 2026). Per share that is €2.55; our models calculate a fair value of €2.02 per share.
What do the bullish and bearish scenarios say about VLA?
Our models span a range for Valneva SE: cautious scenario €1.51, base €2.02, optimistic €2.52 per share (as of Nov 16, 2026, price €2.55). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Valneva SE (VLA)?
Balance-sheet figures for Valneva SE (as of Nov 16, 2026): return on equity −117.9%, debt of 1.52 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is VLA from its 52-week high?
Valneva SE trades at €2.55, about 50% below its 52-week high of €5.08 and 22% above the low of €2.08 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of €2.02 is for.
Which stocks are comparable to Valneva SE?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Valneva SE stock attractive at the current price?
The data as of Nov 16, 2026: price €2.55, calculated fair value €2.02 (−21%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Valneva SE itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Valneva SE (VLA)?
The closing price on Nov 17, 2026 was €2.55. Our estimate is €2.02, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Valneva SE right now?
Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Valneva SE

How large is the market capitalisation of Valneva SE (VLA)?
The market capitalisation of Valneva SE is €484M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Valneva SE (VLA)?
The price-to-sales ratio of Valneva SE is 3.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Valneva SE (VLA)?
Earnings per share at Valneva SE are €−0.9000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Valneva SE (VLA)?
The net margin of Valneva SE is −110% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Valneva SE (VLA)?
The return on equity (ROE) of Valneva SE is −118% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Valneva SE (VLA)?
On an EBIT basis the return on assets of Valneva SE is −12.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Valneva SE (VLA)?
The operating margin of Valneva SE is −74.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Valneva SE (VLA)?
Revenue at Valneva SE is down 27.7% versus a year earlier (3y avg −21.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Valneva SE (VLA)?
Earnings per share at Valneva SE are down 93.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Valneva SE (VLA) generate?
The free cash flow of Valneva SE is −€57.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Valneva SE (VLA) carry?
The net debt of Valneva SE is €97.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Valneva SE in the live analysis

One click puts Valneva SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.